This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Direct purchaser of Colcrys seeks class certification in US antitrust case against Watson, Amneal, others

( September 6, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Value Drug Company asked a US federal judge to certify a proposed class of direct purchasers in a case accusing Watson Laboratories, Amneal Pharmaceuticals, Par Pharmaceuticals, and Takeda of conspiring to delay market entry for a generic version of the anti-inflammatory drug Colcrys. If approved, the class would include anyone who directly purchased branded or generic Colcyrs tablets from Takeda, Prasco, or Par between July 2016 and December 2020.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections